canertinib has been researched along with a 443654 in 1 studies
| Studies (canertinib) | Trials (canertinib) | Recent Studies (post-2010) (canertinib) | Studies (a 443654) | Trials (a 443654) | Recent Studies (post-2010) (a 443654) |
|---|---|---|---|---|---|
| 124 | 9 | 65 | 43 | 0 | 19 |
| Protein | Taxonomy | canertinib (IC50) | a 443654 (IC50) |
|---|---|---|---|
| cAMP-dependent protein kinase catalytic subunit alpha | Bos taurus (cattle) | 0.0165 | |
| RAC-alpha serine/threonine-protein kinase | Homo sapiens (human) | 0.0007 | |
| RAC-beta serine/threonine-protein kinase | Homo sapiens (human) | 0.0152 | |
| RAC-gamma serine/threonine-protein kinase | Homo sapiens (human) | 0.051 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bharate, SB; Raghuvanshi, R | 1 |
1 other study(ies) available for canertinib and a 443654
| Article | Year |
|---|---|
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug Approval; Drug Repositioning; High-Throughput Screening Assays; Humans; Protein Kinase Inhibitors; SARS-CoV-2; United States; United States Food and Drug Administration; Virus Diseases | 2022 |